NASDAQ
Gossamer Bio, Inc. (GOSS)
♥ 607 Thanks from members
Gossamer Bio faces severe liquidity strain and going concern warnings despite a potential FDA filing for seralutinib following a narrow Phase 3 primary endpoint miss, keeping market sentiment highly speculative and cautious.